Sialorrhea is characterized by an increase in salivation. One of the adverse reactions of scopolamine is the decrease of salivary volume. Natural rubber latex can be used as a carrier matrix. This study developed and ...

Objective We studied the frequency of silent laryngeal penetration or silent aspiration (SLP/SA) in Parkinson's disease (PD) patients with diurnal sialorrhea. Patients and methodn In 19 consecutive PD patients with diurnal ...

Sialorrhea or excessive drooling is a significant medical issue in Parkinson’s disease (PD) and neurodegenerative disorders, although it is often underreported by patients. Sialorrhea affects a large proportion of PD ...

This study analysed if botulinum toxin type A (BTX-A) decreases drooling in 21 Parkinson's disease patients. BTX-A injections were given in the parotid glands. The severity of drooling decreased in 18 (86%) patients, while ...

Background: During recent years, sialorrhea in Parkinson's disease (PD) has been treated with botulinum toxin type A (BT-A); however, there are no data describing its effects on swallowing dynamics in this group of ...

Sialorrhea is a disorder which causes an increase in salivation. Scopolamine butylbromide (SBB) can be administrated to treat sialorrhea and its transdermal application minimizes the occurrence of side effects. This work ...